Skip to main content

Table 4 Univariate analysis of clinical characteristics and constitution scores with severe CINV

From: Relationship between traditional Chinese medicine constitutional types with chemotherapy-induced nausea and vomiting in patients with breast cancer: an observational study

  

CINV [n (%)] (n = 612)

 

Grade 0-II (n = 339)

Grade III-IV (n = 273)

P

Age

 

48.5 ± 10.1

48.5 ± 9.7

0.382

Education level

Junior middle school or above

147 (43.4 %)

103 (37.7 %)

0.164

Below junior middle school

192 (56.6 %)

170 (62.3 %)

 

History of breast cancer

Yes

119 (35.1 %)

87 (31.9 %)

0.400

No

220 (64.9 %)

186 (68.1 %)

 

History of vomiting

Yes

77 (22.7 %)

37 (13.6 %)

0.004

No

262 (77.3 %)

236 (86.4 %)

 

KPS score

60–70

262 (77.3 %)

215 (78.7 %)

0.663

70–100

77 (22.7 %)

58 (21.3 %)

 

TNM staging

I

62 (18.3 %)

73 (26.7 %)

0.030

II

199 (58.7 %)

132 (48.3 %)

 

III

58 (17.1 %)

46 (16.9 %)

 

IV

20 (5.9 %)

22 (8.1 %)

 

ER

Positive

102 (30.1 %)

89 (32.6 %)

0.505

Negative

237 (69.9 %)

184 (57.4 %)

 

PR

Positive

145 (42.8 %)

137 (50.2 %)

0.068

Negative

194 (57.2 %)

136 (49.8 %)

 

HER2

Negative

213 (62.8 %)

171 (62.6 %)

0.961

Positive

126 (37.2 %)

102 (37.4 %)

 

P21

Negative

259 (76.4 %)

199 (72.9 %)

0.320

Positive

80 (23.6 %)

74 (27.1 %)

 

P53

Negative

289 (85.3 %)

221 (81.0 %)

0.156

Positive

50 (14.7 %)

52 (19.0 %)

 

PCNA

Negative

267 (78.8 %)

206 (75.5 %)

0.332

Positive

72 (21.2 %)

67 (24.5 %)

 

TCM constitutions

Qi-deficiency

21.3 ± 13.8

22.7 ± 14.4

0.439

Yin-deficiency

20.3 ± 13.7

21.5 ± 11.5

0.001

Wetness-heat

14.6 ± 10.5

17.6 ± 12.5

0.012

Qi-depression

26.3 ± 16.2

29.4 ± 16.0

0.968

Yang-deficiency

18.8 ± 15.8

20.0 ± 16.4

0.341

Blood-stasis

19.3 ± 12.1

21.3 ± 12.4

0.453

Phlegm-wetness

17.3 ± 10.5

18.3 ± 11.5

0.028

Gentleness

69.0 ± 12.7

68.0 ± 13.7

0.275

  1. TNM tumor node metastasis staging, KPS Karnofsky performance status, CINV chemotherapy-induced nausea and vomiting, ER estrogen receptors, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, PCNA proliferating cell nuclear antigen